FDA Approves New Medication for Agitation in Alzheimer's Dementia
The US FDA approved Otsuka and Lundbeck’s brexpiprazole for agitation in Alzheimer’s dementia, addressing a critical behavioral symptom lacking dedicated therapies (https://jamanetwork.com/journals/jama/fullarticle/2849527). This is the first approval for this specific indication. The decision shifts the therapeutic focus from cognition to quality of life.
Drug Profile
Brexpiprazole (Rexulti)
Brexpiprazole is a second-generation (atypical) antipsychotic. Its mechanism of action is not fully elucidated but is attributed to its profile as a serotonin-dopamine activity modulator (SDAM). It functions as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors.
Structurally, it is a dihydrocarbostyril derivative, related to aripiprazole. However, brexpiprazole exhibits lower intrinsic activity at the D2 receptor and higher affinity for the 5-HT1A and 5-HT2A receptors compared to aripiprazole. This distinct receptor-binding profile is theorized to maintain efficacy while potentially mitigating the risk of akathisia and other extrapyral symptoms often associated with D2 receptor modulation. Its approval for this indication is novel; the molecule itself is already approved for schizophrenia and as an adjunctive therapy for major depressive disorder.
Clinical Data
Efficacy was established in two 12-week, randomized, double-blind, placebo-controlled, fixed-dose phase 3 studies in patients with a diagnosis of probable Alzheimer’s disease.
Primary Efficacy Endpoint (https://jamanetwork.com/journals/jama/fullarticle/2849527) | Endpoint | Result (Brexpiprazole) | Comparator (Placebo) | Trial | | :--- | :--- | :--- | :--- | | Change in CMAI Score at Week 12 | -22.6 | -17.3 | 331-12-283 | | Change in CMAI Score at Week 12 | -20.0 | -14.4 | 331-14-213 |
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Regulatory Body | Status | |
| FDA (USA) | ✓ Approved May 24, 2026 | |
| EMA (Europe) | No submission entry detected in BrunoSan DB as of May 24, 2026 | |
| Health Canada | No submission entry detected in BrunoSan DB as of May 24, 2026 | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of May 24, 2026 |
Market Impact
This approval creates a new, formally recognized market segment within Alzheimer's care. Previously, agitation was managed exclusively through off-label use of antipsychotics, antidepressants, and non-pharmacologic interventions. The primary competitors are generic, off-label drugs like risperidone, quetiapine, and citalopram. Brexpiprazole's on-label status provides a substantial commercial advantage, enabling targeted marketing to neurologists and geriatric psychiatrists and likely securing favorable formulary placement from payers seeking to adhere to FDA-sanctioned treatments. The key headwind remains the class-wide boxed warning regarding increased mortality in elderly patients with dementia-related psychosis. Physicians must weigh the demonstrated efficacy against this serious risk, a calculation they already perform for off-label alternatives.
The structural force at play is the bifurcation of the Alzheimer's therapeutic landscape. While high-cost,